Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Cyclophosphamide 28Rituximab 24fludarabine 15fludarabine phosphate 13Specimen Handling 12obinutuzumab 10ibrutinib 10Magnetic Resonance Spectroscopy 10Prednisone 8Mycophenolic Acid 8Doxorubicin 8tocilizumab 7polatuzumab vedotin 7X-Rays 7Whole-Body Irradiation 7Phantoms, Imaging 7Lenalidomide 7Etoposide 7Biopsy 7glofitamab 6Vincristine 6Melphalan 6Busulfan 6Bendamustine Hydrochloride 6venetoclax 5pirtobrutinib 5acalabrutinib 5Peripheral Blood Stem Cell Transplantation 5Nuclear Medicine Department, Hospital 5Nivolumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Non-Hodgkin × efineptakin alfa × 90 days × Clear all
NCT07052305 2026-05-13

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Washington University School of Medicine

Phase 1 Recruiting
24 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡